This study will be conducted in approximately 24 patients chronically infected with hepatitis C virus infection (HCV) and human immunodeficiency virus (HIV). Patient cohorts will receive ascending dose levels of bavituximab weekly for up to 8 weeks. HCV and HIV viral titers and other biomarkers will be evaluated, although they are not formal study endpoints.
Steven King, president and CEO, said: “We are delighted that patient treatment has begun in this important clinical trial that was designed to evaluate an extended bavituximab treatment schedule in an important HCV patient population. We believe that bavituximab has the potential to act on both HCV and HIV infections, and this trial gives us our first opportunity to assess the drug’s anti-viral activity in this underserved group of patients.”